[Development in the treatment of malignant mesothelioma].
For many years there has been a search for an effective treatment of malignant pleural mesothelioma. Surgery is of limited applicability and is reserved for special cases, in which it is combined with radiation therapy. In the previous century, many cytostatic agents have been tested, alone or in combination, but the response was limited, the median survival time was unchanged and the toxicity was high. New drugs, including the new antifolates, are being used much more often in the treatment of malignant pleural mesothelioma in combination with a platinum derivative. Cytostatics such as pemetrexed, an antifolate, and to a lesser extent raltitrexed, have shown good response rates and increased survival in phase III studies, but the survival benefit evaporates within 2 years. Inhibitors of angiogenesis and of epidermal growth factor are being tested, but they have shown only limited activity until now. The current studies focus on the use of chemotherapy and biological agents as part of a more complex treatment schedule.
Bass
P
P
Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, afd Thorax-oncologie, Amsterdam. p.baas@nki.nl
Burgers
J A
JA
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008654:Mesothelioma / Q000601:surgery / Q000628:therapy*; D010997:Pleural Neoplasms / Q000601:surgery / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic